These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 19963387)

  • 41. Cannabinoids in experimental stroke: a systematic review and meta-analysis.
    England TJ; Hind WH; Rasid NA; O'Sullivan SE
    J Cereb Blood Flow Metab; 2015 Mar; 35(3):348-58. PubMed ID: 25492113
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Proof of hazard and proof of safety in toxicological studies using simultaneous confidence intervals for differences and ratios to control.
    Hothorn LA; Hasler M
    J Biopharm Stat; 2008; 18(5):915-33. PubMed ID: 18781525
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design.
    Muir KW
    Stroke; 2002 Jun; 33(6):1545-50. PubMed ID: 12052989
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preclinical drug evaluation for combination therapy in acute stroke using systematic review, meta-analysis, and subsequent experimental testing.
    O'Collins VE; Macleod MR; Cox SF; Van Raay L; Aleksoska E; Donnan GA; Howells DW
    J Cereb Blood Flow Metab; 2011 Mar; 31(3):962-75. PubMed ID: 20978519
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Model-Based Recursive Partitioning for Subgroup Analyses.
    Seibold H; Zeileis A; Hothorn T
    Int J Biostat; 2016 May; 12(1):45-63. PubMed ID: 27227717
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stroke research at a road block: the streets from adversity should be paved with meta-analysis and good laboratory practice.
    Dirnagl U; Macleod MR
    Br J Pharmacol; 2009 Aug; 157(7):1154-6. PubMed ID: 19664136
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Embracing Biological and Methodological Variance in a New Approach to Pre-Clinical Stroke Testing.
    Kent TA; Mandava P
    Transl Stroke Res; 2016 Aug; 7(4):274-83. PubMed ID: 27018014
    [TBL] [Abstract][Full Text] [Related]  

  • 48. How can we improve the pre-clinical development of drugs for stroke?
    Sena E; van der Worp HB; Howells D; Macleod M
    Trends Neurosci; 2007 Sep; 30(9):433-9. PubMed ID: 17765332
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Knowledge level of effect size statistics, confidence intervals and meta-analysis in Spanish academic psychologists.
    Badenes-Ribera L; Frias-Navarro D; Pascual-Soler M; Monterde-I-Bort H
    Psicothema; 2016 Nov; 28(4):448-456. PubMed ID: 27776615
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Stem Cell-Based Therapy for Experimental Ischemic Stroke: A Preclinical Systematic Review.
    Zhang XL; Zhang XG; Huang YR; Zheng YY; Ying PJ; Zhang XJ; Lu X; Wang YJ; Zheng GQ
    Front Cell Neurosci; 2021; 15():628908. PubMed ID: 33935650
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Organizational Update: The NINDS-Sponsored Stroke Preclinical Assessment Network Is Moving to Its Next Stage.
    Bosetti F; Koenig JI; Janis LS; Wright CB
    Stroke; 2021 Dec; 52(12):e842-e843. PubMed ID: 34807746
    [No Abstract]   [Full Text] [Related]  

  • 52. Statistical considerations for preclinical studies.
    Aban IB; George B
    Exp Neurol; 2015 Aug; 270():82-7. PubMed ID: 25725352
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Can you trust your animal study data?
    Peers IS; South MC; Ceuppens PR; Bright JD; Pilling E
    Nat Rev Drug Discov; 2014 Jul; 13(7):560. PubMed ID: 24903777
    [No Abstract]   [Full Text] [Related]  

  • 54. Statistical perspectives: all together not.
    Hopkins WG; Batterham AM; Impellizzeri FM; Pyne DB; Rowlands DS
    Clin Exp Pharmacol Physiol; 2011 Dec; 38(12):914-6; author reply 917-8. PubMed ID: 21933227
    [No Abstract]   [Full Text] [Related]  

  • 55. Clinical trials are too often founded on poor quality pre-clinical research.
    Rothwell PM
    J Neurol; 2005 Sep; 252(9):1115. PubMed ID: 15789130
    [No Abstract]   [Full Text] [Related]  

  • 56. Correction for multiple testing: is there a resolution?
    Streiner DL; Norman GR
    Chest; 2011 Jul; 140(1):16-18. PubMed ID: 21729890
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Society of Toxicologic Pathology's recommendations on statistical analysis of rodent carcinogenicity studies.
    Toxicol Pathol; 2002; 30(3):415-8. PubMed ID: 12051560
    [No Abstract]   [Full Text] [Related]  

  • 58. Mathematical expression and sampling issues of treatment contrasts: Beyond significance testing and meta-analysis to clinically useful research synthesis.
    Krause MS
    Psychother Res; 2018 Jan; 28(1):58-75. PubMed ID: 27581109
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Criteria for valid preclinical trials using animal stroke models.
    Rosenblum WI
    Stroke; 1993 Oct; 24(10):1601-2. PubMed ID: 8378968
    [No Abstract]   [Full Text] [Related]  

  • 60. Calculating unreported confidence intervals for paired data.
    Hirji KF; Fagerland MW
    BMC Med Res Methodol; 2011 May; 11():66. PubMed ID: 21569392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.